IP Library › Granted Patent US 11,746,159
Granted Patent B2
US 11,746,159 · App. 15/549,942 · Granted Sep 5, 2023

Humanized anti-MUC1* antibodies

Inventors: Cynthia Bamdad (Waltham, MA); Benoit Smagghe (Waltham, MA)
Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
C07K16/3092A61K39/00117A61K2039/5156A61K2039/5158C07K2317/24C07K2317/34C07K2317/52C07K2317/622C07K2319/02C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,746,159
App. No.
15/549,942
Granted
Sep 5, 2023
Kind
B2
Abstract

The present application discloses humanized antibodies and antibody like proteins and fragments thereof.

Claims (14)

1. A chimeric antigen receptor (CAR) comprising a scFv or humanized scFv of an MN-E6 scFv set forth as consisting of SEQ ID NOS: 233, 235, or 237, MN-C2 scFv set forth as consisting of SEQ ID NOS:239, 241, or 243, MN-C3 scFv set forth as consisting of SEQ ID NOS: 245, 247, or 249 or MN-C8 scFv set forth as consisting of SEQ ID NOS:251, 253, or 255.

2. The CAR as in claim 1 , further comprising a cytoplasmic tail comprising one or more of signaling sequence motifs selected from the group consisting of:

CD3-zeta, CD27, CD28, 4-1BB, 0X40, CD30, CD40, PD-1, ICAm-1, LFA-1, ICOS, CD2, CDS, and CD7.

3. The CAR as in claim 1 , wherein its sequence is CARIVIN-E6 CD3z (SEQ ID NO:295), CARIVIN-E6 CD28/CD3z (SEQ ID NO :298); CARMN-E6 4-1BB/CD3z (SEQ ID NO :301); CARMN-E6 0X40/CD3z (SEQ ID NO :617); CARMN-E6 CD28/4-1BB/CD3z (SEQ ID NO :304); CARMN-E6 CD28/0X40/CD3z (SEQ ID N0:619); CAR MN-C2 CD3z (SEQ ID NO :607); CAR MN-C2 CD28/CD3z (SEQ ID N0:609); CAR MN-C2 4-1BB/CD3z (SEQ ID NO :611); CAR MN-C2 0X40/CD3z (SEQ ID NO :613); CAR MN-C2 CD28/4-1BB/CD3z (SEQ ID NO :307); or CAR MN-C2 CD28/0X40/CD3z (SEQ ID NO :615).

4. A cell comprising the CAR of claim 1 .

5. The cell according to claim 4 , wherein the cell comprising the CAR is an immune system cell.

6. The cell according to claim 5 , wherein the immune system cell comprising the CAR is T cell.

7. The cell according to claim 5 , wherein the immune system cell comprising the CAR is dendritic cell.

8. The cell according to claim 5 , wherein the immune system cell comprising the CAR is mast cell.

9. The CAR as in claim 1 , wherein the scFv or humanized scFv is of the MN-C2 scFv set forth as consisting of SEQ ID NOS:239, 241, or 243.

10. The CAR as in claim 1 , wherein the scFv or humanized scFv is of the MN-E6 scFv set forth as consisting of SEQ ID NOS: 233, 235, or 237.

11. The CAR as in claim 1 , wherein the scFv or humanized scFv is of the MN-C3 scFv set forth as consisting of SEQ ID NOS: 245, 247, or 249.

12. The CAR as in claim 1 , wherein the scFv or humanized scFv is of the MN-C8 scFv set forth as consisting of SEQ ID NOS:251, 253, or 255.

13. The CAR of claim 3 , wherein its sequence is CAR MN-C2 4-1BB/CD3z (SEQ ID NO :611).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2018
From: BAMDAD, CYNTHIA; SMAGGHE, BENOIT
To: MINERVA BIOTECHNOLOGIES CORPORATION
Reel/Frame 047498/0091 →
Continuity (2)
Provisional Application 62114526 · Feb 10, 2015
Related Publication 20180112007A1 · Apr 26, 2018
Cited By (2)
US 12,415,868 US 12,491,259